SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

SKYE

Skye Bioscience, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss and accelerating cash burn without a clear funding path for Phase 2b are negative signals. Monitor the May 18 CRC review for Cohort 1 safety data, a positive read could provide a near-term catalyst, but the fundamental cash constraint limits upside until a financing event occurs.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.8140
T+0 close · May 12, 2026 · via day close
Latest settled
−42.05%
T+60 · $0.4717
Vs SPY
−46.44%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $0.8140entry
  2. T+1 · 6mo ago +0.74%α +0.16% · $0.8200
  3. T+5 · 6mo ago −4.42%α −4.50% · $0.7780
  4. T+20 · 5mo ago −4.18%α −2.45% · $0.7800
  5. T+60 · 3mo ago −42.05%α −46.44% · $0.4717
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Skye Bioscience reported Q1 2026 EPS of -$0.32, missing consensus of -$0.29 by 10.3%, with a net loss of $12.5M vs $11.1M a year ago. The company highlighted clinical progress in its CBeyond expansion study for nimacimab but faces a cash runway only through Q4 2026, excluding Phase 2b costs, creating significant funding uncertainty.

Key Financial Metrics

EPS
−$0.32
est −$0.29 · -10.3%
Rating
miss

Key Facts

  • Q1 2026 EPS -$0.32 vs consensus -$0.29 (10.3% miss)
  • Net loss widened to $12.5M from $11.1M YoY
  • Cash, equivalents and short-term investments: $17.1M as of March 31, 2026
  • Cash runway only through Q4 2026, excluding Phase 2b costs
  • R&D expenses rose to $7.9M from $7.2M YoY
  • CBeyond Expansion Study Cohort 1 enrollment initiated; CRC review May 18, 2026
  • Topline data from CBeyond Expansion Study expected Q4 2026
  • Weighted average shares outstanding: 39.7M (basic and diluted)

Financial Impact

EPS miss of $0.03 per share; net loss increased by $1.4M YoY; cash burn rate ~$4.3M/month

epsnetLosscashRunway

Risk Factors

  • Cash runway only through Q4 2026, requiring dilutive financing or partnership to fund Phase 2b
  • EPS miss of 10.3% vs consensus signals operational underperformance
  • Net loss widening YoY with no near-term revenue prospects
  • Clinical trial risk: nimacimab may fail to meet safety/efficacy endpoints in expansion study

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293281

Track record

16 reports on SKYE

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago DEFA14A Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  2. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  3. Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
  4. Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
  5. Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
  6. Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
  7. Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
  8. Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
  9. Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
  10. Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026